Cargando…

First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony

BACKGROUND: Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an immunomodulator) was more effective than pentavalent ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miranda-Verastegui, Cesar, Tulliano, GianFranco, Gyorkos, Theresa W., Calderon, Wessmark, Rahme, Elham, Ward, Brian, Cruz, Maria, Llanos-Cuentas, Alejandro, Matlashewski, Greg
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710502/ https://www.ncbi.nlm.nih.gov/pubmed/19636365 http://dx.doi.org/10.1371/journal.pntd.0000491

Ejemplares similares

New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony
por: Shin, Ji Yeon, et al.
Publicado: (2013)

Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review
por: Brito, Nayara Castelano, et al.
Publicado: (2017)

Assessment of Immune and Clinical Response in Patients with Mucosal Leishmaniasis Treated with Pentavalent Antimony and Pentoxifylline
por: Cincura, Carolina, et al.
Publicado: (2022)

The Pentavalent Antimony Compounds in Tropical Medicine
por: Schmidt, Hans
Publicado: (1928)

Renal function evaluation in patients with American Cutaneous Leishmaniasis after specific treatment with pentavalent antimonial
por: Oliveira, Rodrigo A, et al.
Publicado: (2012)

Prediction Score for Antimony Treatment Failure in Patients with Ulcerative Leishmaniasis Lesions
por: Valencia, Cristian, et al.
Publicado: (2012)

Pentavalent Antimonials: New Perspectives for Old Drugs
por: Frézard, Frédéric, et al.
Publicado: (2009)

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review
por: Berbert, Taisa Rocha Navasconi, et al.
Publicado: (2018)

American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
por: Marques, Sílvio Alencar, et al.
Publicado: (2019)

A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis
por: Rodrigues, Bruna Côrtes, et al.
Publicado: (2020)

Novel Low-Cost Thermotherapy for Cutaneous Leishmaniasis in Peru
por: Valencia, Braulio M., et al.
Publicado: (2013)

Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
por: Ferreira, Weverson A., et al.
Publicado: (2014)

A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
por: Martins, Sofia Sales, et al.
Publicado: (2021)

Risk factors for cutaneous leishmaniasis in a high-altitude forest region of Peru
por: Lana, Justin T., et al.
Publicado: (2021)

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a Leishmania infantum Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy
por: Diotallevi, Aurora, et al.
Publicado: (2021)

The Extraordinary Case of a Woman with a 30-Year-Long Diffuse Leishmaniasis Cured with One Single Ampoule of Intranasal Pentavalent Antimoniate
por: Gonçalves, Sheila V. C. B., et al.
Publicado: (2023)

The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
por: Zhang, Li, et al.
Publicado: (2015)

Reactions Following the Administration of the Pentavalent Compounds of Antimony: An Analysis of Cases Reported by Several Correspondents
por: Napier, L. Everard
Publicado: (1926)

CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis
por: Thacker, Seth G, et al.
Publicado: (2020)

“Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia
por: Eid Rodríguez, Daniel, et al.
Publicado: (2019)

The effect of deworming on early childhood development in Peru: A randomized controlled trial
por: Joseph, Serene A., et al.
Publicado: (2015)

Non-Invasive Cytology Brush PCR for the Diagnosis and Causative Species Identification of American Cutaneous Leishmaniasis in Peru
por: Valencia, Braulio Mark, et al.
Publicado: (2012)

In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
por: Carrió, Jaume, et al.
Publicado: (2002)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
por: Avcilar, Huseyin, et al.
Publicado: (2020)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Evaluation of a diagnostic device, CL Detect rapid test for the diagnosis of new world cutaneous leishmaniasis in Peru
por: Grogl, Max, et al.
Publicado: (2023)

Old World Cutaneous Leishmaniasis: Successful response to topical imiquimod
por: Llamas-Molina, Jose M., et al.
Publicado: (2022)

Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
por: Haldar, Arun Kumar, et al.
Publicado: (2011)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis
por: Maristany Bosch, Marta, et al.
Publicado: (2021)

The Effect of Deworming on Growth in One-Year-Old Children Living in a Soil-Transmitted Helminth-Endemic Area of Peru: A Randomized Controlled Trial
por: Joseph, Serene A., et al.
Publicado: (2015)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Ramsey hunt syndrome after antimonial treatment for American Cutaneous Leishmaniasis
por: Cavalcante, Melissa de Sousa Melo, et al.
Publicado: (2020)

Tegumentary leishmaniasis and coinfections other than HIV
por: Martínez, Dalila Y., et al.
Publicado: (2018)

Non-Invasive Cytology Brush PCR Diagnostic Testing in Mucosal Leishmaniasis: Superior Performance to Conventional Biopsy with Histopathology
por: Boggild, Andrea K., et al.
Publicado: (2011)

Epidemiology of Plasmodium vivax Malaria in Peru
por: Rosas-Aguirre, Angel, et al.
Publicado: (2016)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
por: Yazdanpanah, Mohamad Javad, et al.
Publicado: (2011)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
por: Vasconcellos, Erica de Camargo Ferreira e, et al.
Publicado: (2014)

Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina
por: García-Bustos, María F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ccneo5cv071bdg8br2ns007ppe